AKTX — Akari Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Samir Patel Appointed Interim CEO For Akari Therapeutics
Brief: Akari Therapeutics And Peak Bio Announce Portfolio Prioritization Plan For Combined Go-Forward Merger Entity
Brief: Akari Therapeutics Agrees To Sell And Issue In A Private Placement Approximately $1.6 Million ADSS
Brief: Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. To Board Of Directors
Brief: Akari Therapeutics Files Prospectus Relates To Resale, By Selling Shareholders, Of Upto Total Of 642,753 ADS, Representing 1.3 Billion Ordinary Shares
Akari Therapeutics PLC expected to post a loss of $1.20 a share - Earnings Preview
Regains Compliance With Nasdaq Minimum Bid Price Requirement
Brief: Akari Therapeutics Announces Establishment Of Boston U.S. Headquarters Office
Brief: Akari Therapeutics PLC Announces ADS Ratio Change
Brief: Akari Therapeutics Says Nomacopan Receives Orphan Drug Designation From European Commission
Brief: Akari Therapeutics Appoints Wendy Dicicco As Interim CFO
Akari Therapeutics PLC expected to post a loss of 6 cents a share - Earnings Preview
Brief: Akari Therapeutics Provides Updates On Development Of Nomacopan In Pediatric And Adult HSCT-TMA
Brief: Akari Therapeutics Provides Update On Development Of PAS-Nomacopan
Brief: Akari Therapeutics Receives Positive Opinion On Orphan Drug Designation From The European Medicines Agency For Nomacopan For Treatment In Hematopoietic Stem Cell Transplantation
Brief: Aspira Women's Health Names Torsten Hombeck As Chief Financial Officer
Brief: Akari Therapeutics Says On May 1, Torsten Hombeck, CFO, Delivered Notice Of Resignation
Brief: Akari Therapeutics Granted 180-Day Extension By Nasdaq To Meet Minimum Bid Price Requirement
Akari Therapeutics PLC expected to post a loss of 4 cents a share - Earnings Preview